Swim with the Funds: The story of funding from those who succeeded
Swim with the Funds: The story of funding from those who succeeded
Johnson & Johnson Innovation, JLABS , 329 Oyster Point Blvd , South San Francisco , CA
June 21, 2016 from 12:00 PM to 14:30 PM (PDT)
$10 - $35
Without it your startup will not float. There are many sources of funding including Angels, VC's, governments, incubators, Pharma, friends and family, etc… but how do you get it? What source(s) are best for your company?
Johnson & Johnson Innovation, JLABS is fortunate to have a breadth of startups with a wide range of funding experience, so we asked them to share their inner funding thoughts and secrets. Joins us for a deep dive to look how current startups are succeeding at the funding game and how they plan to continue to keep their head above water.
- Where did you start?
- How does one offer effect interest from others?
- Angel vs. Friend/family vs. VC's vs. incubators
- Seed- series A, B, and beyond when is it best to have one investor lead the round?
- Do funding methods differ depending on the product: med-device/instrument, bioinformatics software, biologic drug or therapeutic.
- The process – how many times did you get up to the plate before you got on base?
- How about non-accredited investors/crowd sourcing?
10:00am | Registration Opens and Networking
10:30am | Introduction
10:35am | Panel
11:30am | Q&A
11:45am | Lunch & Networking
12:30pm | Program Close
Caleb Bell | CEO and Co-founder, Bell Biosystems read bio»
Colleen Cutcliffe | CEO and Co-founder, Whole Biome read bio»
Tim Hsiao | Small Business Innovation Specialist, NIH/NIAID read bio»
Casey Lynch | CEO and Co-founder, Cortexyme read bio»
[moderator] Laura Brege | Managing Director, Cervantes Life Science Partners read bio»
$20 | General Public
$30 | Onsite
JLABS @ SSF
329 Oyster Point Blvd - 3rd Floor
South San Francisco, California
Caleb B. Bell III | Chief Executive Officer and Co-founder, Bell Biosystems
Caleb has served as CEO of Bell Biosystems since co-founding the company. Under Caleb's leadership, Bell Biosystems has been recognized by the White House for its "Breakthrough" in life science technologies, as a 2014 Rising Star by BayBio, and as a "biotech on the cusp of something big" by the San Francisco Business Times. Caleb sits on the board of trustees of BayBio and founded three companies prior to Bell Biosystems, serving as CEO of one for six years. He is a well published scientist and named inventor on multiple issued patents. Caleb earned a Ph.D. in Biophysical Chemistry from Stanford University, completed the Stanford University Graduate School of Business Ignite program, and received a B.S. in Biochemistry and Molecular Biology from Penn State University.
Connect with Caleb:
Colleen Cutcliffe | Chief Executive Officer and Co-founder, Whole Biome
Colleen Cutcliffe is the co-founder and CEO of Whole Biome, an early stage microbiome company. Colleen has over a decade of experience managing and directing fundamental biology research teams in the academic, pharmaceutical and biotech sectors. Prior to starting Whole Biome, Colleen served as the Senior Manager of Biology at Pacific Biosciences, a Scientist at Elan Pharmaceuticals and a Postdoctoral Fellow at Chicago's Children's Memorial Hospital. Colleen received her Ph.D. in Biochemistry and Molecular Biology from Johns Hopkins University and her B.A. in Biochemistry from Wellesley College.
Connect with Colleen:
H. Timothy Hsiao | Small Business Innovation Specialist, NIH/NIAID
Tim manages various initiatives, including the I-Corps program at NIAID, to strengthen the portfolio performance of federal investments in biomedical small business innovation research/technology transfer (SBIR/STTR). He also conducts portfolio analysis and leads a trans-NIH working group to help shape NIH's evaluation metrics for SBIR/STTR commercialization success. He developed his expertise in innovation policy and public-private partnership through his prior services as an Innovation Policy Officer (Economic Section of the U.S. Embassy in Mexico City) and a Science & Technology Policy Fellow (American Association for the Advancement of Science). He holds a Ph.D. in Molecular Biophysics & Biochemistry from Yale University, and is affiliated with NIAID Division of Extramural Research's Office of Research Training and Special Programs (Contract-based).
Connect with Tim:
Casey Lynch | Chief Executive Officer and Co-founder, Cortexyme
Casey Lynch is the co-founder and CEO of Cortexyme, a privately funded company developing novel treatments and diagnostics for Alzheimer's disease and other degenerative disorders. Casey was the co-founder and Managing Director of NeuroInsights and Aspira Biosystems. Aspira was acquired by Nanomune Inc. in 2004. Casey oversaw toxicology screening and evaluated new product opportunities at Centaur Pharmaceuticals where she established disease model testing paradigms for multiple sclerosis, uveitis, and other neurological disorders. Casey conducted primate preclinical trials for Alzheimer's disease treatment at the Wadsworth Medical Center in Los Angeles and researched the neurological basis of schizophrenia and epilepsy at UCLA. She has worked with companies on partnering and fundraising as well as investors to identify and profit from opportunities in commercial neuroscience through consulting, conferences, and publications. Casey has a BS in neuroscience from UCLA, and an MS in neuroscience from UCSF doing research in the Mobley lab at UCSF/ Stanford University where her graduate research focused on neurotrophic factor cell biology and neurodegenerative diseases. She has completed the Management Development for Entrepreneurs (MDE) program of the Anderson School of Business. Casey is on the Board of Directors of The Neurotechnology Industry Organization, a trade association for commercial neuroscience.
Connect with Casey:
[moderator] Laura Brege | Managing Director, Cervantes Life Science Partners
Laura Brege has over 25 years of executive management experience in the pharmaceutical, biotechnology and venture capital industries. Most recently, Ms. Brege was President & CEO of Nodality, Inc., a private company focused on innovative personalized medicine approaches in oncology, immunology and immuno-oncology. Prior to joining Nodality, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals, Inc., a global oncology company, including Executive Vice President and Chief Operating Officer. While at Onyx, she led multiple functions, including commercialization, strategic planning, corporate development, technical operations and medical, scientific and government affairs. Prior to Onyx, Ms. Brege was a General Partner at Red Rock Capital Management, a venture capital firm investing in early stage technology companies. Previously Ms. Brege was CFO at COR Therapeutics, helping build the company from an early stage R&D company through commercial launch of a successful cardiovascular product. Earlier she served as CFO at Flextronics, Inc. and Treasurer of The Cooper Companies. Ms. Brege serves on the Board of Directors of Acadia Pharmaceuticals, Aratana Therapeutics, Dynavax Technologies, Portola Pharmaceuticals and Pacira Pharmaceuticals. She served on the Board of California Life Sciences Association (CLSA). Ms. Brege received her MBA from The University of Chicago and her undergraduate degree from Ohio University, Honors Tutorial College.